Sec. 2033. INCREASING ACCOUNTABILITY AT THE NATIONAL INSTITUTES OF HEALTH
864 words·~4 min read·
/statute-compilations/comps-13005/sec-2033A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
## SEC. 2033 INCREASING ACCOUNTABILITY AT THE NATIONAL INSTITUTES OF HEALTH ###
(a)Appointment and Terms of Directors of National Research Institutes and National Centers Subsection
(a)of section 405 of the Public Health Service Act (42 U.S.C. 284) is amended to read as follows: > > ### “(a) Appointment > > > #### “(1) In general > > The Director of the National Cancer Institute shall be appointed by the President, and the Directors of the other national research institutes and national centers shall be appointed by the Secretary, acting through the Director of National Institutes of Health. Each Director of a national research institute or national center shall report directly to the Director of National Institutes of Health. > > > #### “(2) Appointment > > > ##### “(A) Term > > A Director of a national research institute or national center who is appointed by the Secretary, acting through the Director of National Institutes of Health, shall be appointed for 5 years. > > > ##### “(B) Reappointment > > At the end of the term of a Director of a national research institute or national center, the Director may be reappointed in accordance with standards applicable to the relevant appointment mechanism. There shall be no limit on the number of terms that a Director may serve. > > > ##### “(C) Vacancies > > If the office of a Director of a national research institute or national center becomes vacant before the end of such Director’s term, the Director appointed to fill the vacancy shall be appointed for a 5-year term starting on the date of such appointment. > > > ##### “(D) Current directors > > Each Director of a national research institute or national center who is serving on the date of enactment of the 21st Century Cures Act shall be deemed to be appointed for a 5-year term under this subsection beginning on such date of enactment. > > > ##### “(E) Rule of construction > > Nothing in this subsection shall be construed to limit the authority of the Secretary or the Director of National Institutes of Health to terminate the appointment of a director referred to in subparagraph
(A)before the expiration of such director’s 5-year term. > > > ##### “(F) Nature of appointment > > Appointments and reappointments under this subsection shall be made on the basis of ability and experience as it relates to the mission of the National Institutes of Health and its components, including compliance with any legal requirement that the Secretary or Director of National Institutes of Health determines relevant. > > > #### “(3) Nonapplication of certain provision > > The restrictions contained in section 202 of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 1993 (Public Law 102-394; 42 U.S.C. 238f note) related to consultants and individual scientists appointed for limited periods of time shall not apply to Directors appointed under this subsection.” > . ###
(b)Review of Certain Awards by Directors Section 405(b) of the Public Health Service Act (42 U.S.C. 284(b)) is amended by adding at the end the following: > > #### “(3) > > Before an award is made by a national research institute or by a national center for a grant for a research program or project (commonly referred to as an ‘R-series grant’), other than an award constituting a noncompetitive renewal of such a grant, or a noncompetitive administrative supplement to such a grant, the Director of such national research institute or national center shall, consistent with the peer review process— > > > ##### “(A) > > review and make the final decision with respect to making the award; and > > > ##### “(B) > > take into consideration, as appropriate— > > > ###### “(i) > > the mission of the national research institute or national center and the scientific priorities identified in the strategic plan under section 402(m); > > > ###### “(ii) > > programs or projects funded by other agencies on similar research topics; and > > > ###### “(iii) > > advice by staff and the advisory council or board of such national research institute or national center.” > . ###
(c)Report on Duplication in Federal Biomedical Research The Secretary of Health and Human Services (referred to in this subsection as the “Secretary”), shall, not later than 2 years after the date of enactment of this Act, submit a report to Congress on efforts to prevent and eliminate duplicative biomedical research that is not necessary for scientific purposes. Such report shall— ####
(1)describe the procedures in place to identify such duplicative research, including procedures for monitoring research applications and funded research awards to prevent unnecessary duplication; ####
(2)describe the steps taken to improve the procedures described in paragraph (1), in response to relevant recommendations made by the Comptroller General of the United States; ####
(3)describe how the Secretary operationally distinguishes necessary and appropriate scientific replication from unnecessary duplication; and ####
(4)provide examples of instances where the Secretary has identified unnecessarily duplicative research and the steps taken to eliminate the unnecessary duplication.
Connectionstraces to 2
Traces to 2 documents
1 reference not yet in our index
- Pub. L. 102-394
Citation graph
cites case law
Sec. 2033
INCREASING ACCOUNTABILITY AT THE NATIONAL INSTITUTES OF HEALTH
Pub. L.Pub. L. 102-394
Cites 3Cited by 0 across 0 sources